In CombiGene’s Q3 report, the terminated agreement with Spark Therapeutics takes up considerable space, for obvious

CombiGene has chosen Charles River Laboratories as a partner for the peptide-based pain project COZY01, which

Over the weekend, CombiGene received the news that Spark Therapeutics has terminated the collaboration agreement for

See the interview with CEO Peter Ekolind at BioStock Investor Meeting here: BioStock Investor Meeting |

CombiGene has entered into a partnership with AmbioPharm, a US-based contract manufacturer for the COZY01 peptide-based

Jan Nilsson, CEO of gene therapy company CombiGene since 2016, has left his post and last

At the beginning of 2023, CombiGene’s CEO Jan Nilsson and Zyneyro’s CEO Peter Horn Møller signed

CombiGene’s CEO, Jan Nilsson, has been appointed Chairman of CCRM Nordic, Centre for Commercialization of Regenerative

CombiGene recently achieved a milestone with the publication of a scientific article in Gene Therapy, a

At the beginning of the year, CombiGene and Zyneyro entered into a collaboration for the development